Close this search box.
Follow us




Rheumatoid Arthritis is a systemic disease, occurs when immune system mistakenly attacks its own healthy cells, especially the lining of the joints which named by synovium or synovial membrane.

Rheumatoid Arthritis affects the lining of your joints, causing a chronic painful swelling that can eventually result in joint deformity and bone erosion. Rheumatoid arthritis (RA) represents a chronic inflammatory disease that can attack more than just your joints. Sometimes Rheumatoid Arthritis’s inflammation can damage the other part of body as well, the eyes, skin, lungs, blood vessels and heart. The disease can lead to disability, decreased quality of life and premature mortality due to joint deformity and bone erosion. Each year 71 out of 100,000 persons are being diagnosed with Rheumatoid Arthritis, according to an estimate 1.5 million Americans are dealing with Rheumatoid Arthritis. Estimates show that prevalence incidence of Rheumatoid Arthritis in women is 2 or 3 times higher than men, which may it’s due to differential sexual hormones levels that play an important role in triggering or preventing it. Women generally are being diagnosed with RA between the ages of 30 and 60, which is a little bite later in men. However, Rheumatoid arthritis can present at any age, even children can develop it. Based on European Alliance of Associations for Rheumatology recommendations, following failure of one or more conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) and in the presence of at least one poor prognostic factor, a biological DMARD (bDMARD) or a Janus kinase (JAK) inhibitor should be started. Tofacitinib is an oral Janus kinase (JAK) inhibitor which is approved for the treatment of RA.

Hence, one of Parsian’s fields of activity is research and development in RA to manufacture active pharmaceutical ingredients (API) of RA medicines with the highest global standards to help patients who are battling with RA to have fewer concerns by the latest guidelines and with the lowest adverse effects.



Tofacitinib citrate


Cas No: 540737-29-9

Mechanism Of Action: Tofacitinib exerts its mechanism of action by inhibiting intracellular cytoplasmic non-receptor tyrosine kinase JAK enzymes, which are involved in adaptive and innate